Abstract
Despite advances in HAART, patients with HIV infection remain at significantly increased risk for intermediate- and high-grade B-cell non-Hodgkin lymphoma. The reasons for this persistent risk and the clinical and molecular correlates that predict outcomes and treatment responsiveness are areas of active investigation. Here we review the epidemiologic and pathobiologic features of AIDS-related lymphoma along with clinical evaluation and treatment options in patients with this disease.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Antiretroviral Therapy, Highly Active*
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
HIV Infections / drug therapy
-
Humans
-
Incidence
-
Lymphoma, AIDS-Related / diagnostic imaging
-
Lymphoma, AIDS-Related / drug therapy*
-
Lymphoma, AIDS-Related / epidemiology*
-
Lymphoma, AIDS-Related / etiology
-
Lymphoma, AIDS-Related / pathology
-
Male
-
Middle Aged
-
Prednisone / administration & dosage
-
Radiography
-
Registries
-
United States / epidemiology
-
Vincristine / administration & dosage
Substances
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone